Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381

Author：  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.10, Iss.1, 2010-05, pp. : 33-36

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

By Rennings Alexander JM   Stalenhoef Anton FH  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 10, 2008-10 ,pp. : 1589-1597

Informa Healthcare

Access to resources Recommend Favorite

Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals

By Okamoto H.   Iwamoto Y.   Maki M.   Sotani T.   Yonemori F.   Wakitani K.  

European Journal of Pharmacology, Vol. 466, Iss. 1, 2003-04 ,pp. : 147-154

Elsevier

Access to resources Recommend Favorite

Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative

By Shibata T.   Matsui K.   Nagao K.   Shinkai H.   Yonemori F.   Wakitani K.  

European Journal of Pharmacology, Vol. 364, Iss. 2, 1999-01 ,pp. : 211-219

Elsevier

Access to resources Recommend Favorite

Triglyceride-lowering effect of a novel insulin-sensitizing agent, JTT-501

By Shibata T.   Matsui K.   Yonemori F.   Wakitani K.  

European Journal of Pharmacology, Vol. 373, Iss. 1, 1999-05 ,pp. : 85-91

Elsevier

Access to resources Recommend Favorite

Glucose-dependent insulinotropic effects of JTT-608, a novel antidiabetic compound

By Furukawa N.   Ohta T.   Noguchi T.   Yonemori F.   Wakitani K.  

European Journal of Pharmacology, Vol. 371, Iss. 1, 1999-04 ,pp. : 51-58

Elsevier

Access to resources Recommend Favorite